StreetAlpha.app
Home › Stocks › PHVS

Pharvaris N.V. (PHVS)

Healthcare
$31.28
▼ −1.20%
LAST CLOSE · NOV 20

Pharvaris develops drug candidates for hereditary angioedema, a rare condition that causes episodes of severe swelling. It last closed at $31.28 on Nov 20, down 1.20% on the day. Over the last 12 months PHVS insiders bought $0 of stock on the open market and sold $33.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is PHVS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PHVS.

Key Stats

Last 12 months
Results
Net income
−EUR 175.7M
Free cash flow
−EUR 137.2M
Balance sheet
Cash & equivalents
EUR 291.7M
At Dec 31
Shareholder equity
EUR 271.3M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −EUR 42.7M−EUR 42.7MFY2021FY2022: −EUR 76.3M−EUR 76.3MFY2022FY2023: −EUR 100.9M−EUR 100.9MFY2023FY2024: −EUR 134.2M−EUR 134.2MFY2024FY2025: −EUR 175.7M−EUR 175.7MFY2025

From PHVS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Apr 2). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PHVS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PHVS

Technical Analysis

PHVS · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 5% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 41). The nearest support is the Pivot at $31.23, and the nearest resistance the 200 day average at $31.46.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 4.8%/day
Key levels
$43.2552 week high+38.3%
$33.88100 day average+8.3%
$33.1020 day average+5.8%
$32.7050 day average+4.5%
$32.20Swing high (Jun 4)+2.9%
$32.04Pivot R1+2.4%
$31.46200 day average+0.6%
$31.28Last close
$31.23Pivot−0.2%
$30.49Swing low (Jun 15)−2.5%
$30.48Pivot S1−2.6%
$23.1552 week low−26.0%
Indicators
RSI (14)40.78Middle of its rangeNeutral
MACD-0.13Below its signal lineBearish
Stochastic11.7Near the bottom of its rangeOversold
ADX (14)16.8No clear trend
Williams %R-83.1Oversold below −80, overbought above −20Oversold
CCI (20)-140.3Oversold below −100, overbought above 100Oversold
Rate of change−9.0%Change over 10 sessionsBearish
ATR (14)$1.50Typical daily range, 4.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PHVS

What happened before

See how PHVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PHVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PHVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PHVSHow many large options trades hit PHVS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PHVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲80 buying vs 47 selling
  • ▲Shares held by funds +3.8%
  • ▲Funds holding +10
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding135125+8.0%
In funds' top 101514+7.1%
Held by funds–––
New / increased22 / 5823 / 47+14.3%
Reduced / sold out34 / 1333 / 10+9.3%
Put/call ratio1.39––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PHVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PHVS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$33.0M43 sales · 11 insiders
46% of the selling was under pre-arranged trading plans.
2026-04 sold $4.6M2026-05 sold $2.5M2026-06 sold $5.5M2026-07 sold $80K2026-08 sold $80K2026-09 sold $20.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 23Viviane MongesDirectorSale11,969$33.05$396K
Sep 22Johannes Gerardus Christiaan Petrus SchikanDirectorSale800$36.19$29K
Sep 21David W. NassifCFO / CloSale6,000$36.47$219K
Sep 17Anne LesageChief Early DevelopmentSale20,000$38.27$765K
Sep 17Robert GlassmanDirectorSale14,493$38.56$559K
Sep 17Elisabeth BjorkDirectorSale52,500$37.89$2.0M
Every insider buy and sale for PHVS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PHVS insider trades →

From SEC Form 4 filings by PHVS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PHVS is in one of them and how their past PHVS trades turned out.

PHVS in the AI portfolios
Loading…

PHVS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PHVS in an article yet. Here's the latest on the wider market.

PHVS in the news

About Pharvaris N.V.

Pharvaris is a pharmaceutical company based in Leiden that is developing treatments for hereditary angioedema, a rare condition that causes episodes of severe swelling. Its product candidates, including IR and XR, are still in clinical development and have not yet received marketing approval. If approved, they would be sold to patients and physicians, with insurers and other payors deciding how much coverage to provide. The company intends them to be used alongside or in place of existing therapies.

Headquarters
Leiden